An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies

Roy B. Tishler, Paul M. Busse, Charles M. Norris, René́ Rossi, Mark Poulin, Lee Thornhill, Rosemary Costello, Edward S. Peters, A. Dimitrios Colevas, Marshall R. Posner

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Combined modality therapy plays a central role in the management of head and neck malignancies. This study examined the feasibility and preliminary results of treating a group of patients using concurrent bolus paclitaxel (Taxol(TM)) and radiation therapy. Methods: Fourteen patients with a median age of 56 years (range 42-81) were treated. Paclitaxel was given every 3 weeks at a dose of 100 mg/m2 concurrently with external beam radiation. The patients treated included those who had failed to achieve a complete response (CR) to induction chemotherapy with cisplatin, 5- fluorouracil, and leucovorin (PFL), or who had locally advanced disease not previously treated. Results: Median follow-up from the initiation of treatment is 40 months (range 23-48). The majority of patients (13/14) achieved clinical CRs at the primary site. The development of responses was characterized by a long time course. Three patients who were nonresponders (NRs) to induction PFL chemotherapy were treated. One was a clinical CR at the primary site, one did not achieve a CR, and the other had residual disease in the neck. Four patients have failed, one with local-regional disease, one with a marginal failure, one with distant metastases, and one was not rendered disease-free by the treatment. As expected, significant local toxicity was observed. Most patients were managed with the aid of a percutaneous endoscopic gastrostomy (PEG). Two patients experienced significant moist desquamation and required treatment breaks of greater than 1 week. Conclusion: Paclitaxel can be given on a 3-week schedule at 100 mg/m2 concurrently with radiation. The preliminary results indicate good local responses and acceptable toxicity. This treatment approach merits further study in the treatment of head and neck malignancies, and should be considered as an option in other sites.

Original languageEnglish (US)
Pages (from-to)1001-1008
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume43
Issue number5
DOIs
StatePublished - Mar 15 1999

Fingerprint

Paclitaxel
Neck
Head
Radiation
radiation
Neoplasms
Induction Chemotherapy
Therapeutics
chemotherapy
toxicity
induction
Combined Modality Therapy
Gastrostomy
Leucovorin
Feasibility Studies
metastasis
schedules
Fluorouracil
Cisplatin
radiation therapy

Keywords

  • Combined modality therapy
  • Head and neck
  • Paclitaxel
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. / Tishler, Roy B.; Busse, Paul M.; Norris, Charles M.; Rossi, René́; Poulin, Mark; Thornhill, Lee; Costello, Rosemary; Peters, Edward S.; Colevas, A. Dimitrios; Posner, Marshall R.

In: International Journal of Radiation Oncology Biology Physics, Vol. 43, No. 5, 15.03.1999, p. 1001-1008.

Research output: Contribution to journalArticle

Tishler, RB, Busse, PM, Norris, CM, Rossi, R, Poulin, M, Thornhill, L, Costello, R, Peters, ES, Colevas, AD & Posner, MR 1999, 'An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies', International Journal of Radiation Oncology Biology Physics, vol. 43, no. 5, pp. 1001-1008. https://doi.org/10.1016/S0360-3016(98)00533-1
Tishler, Roy B. ; Busse, Paul M. ; Norris, Charles M. ; Rossi, René́ ; Poulin, Mark ; Thornhill, Lee ; Costello, Rosemary ; Peters, Edward S. ; Colevas, A. Dimitrios ; Posner, Marshall R. / An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. In: International Journal of Radiation Oncology Biology Physics. 1999 ; Vol. 43, No. 5. pp. 1001-1008.
@article{fcb5ea80c8ea488f929636106edad6c4,
title = "An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies",
abstract = "Background: Combined modality therapy plays a central role in the management of head and neck malignancies. This study examined the feasibility and preliminary results of treating a group of patients using concurrent bolus paclitaxel (Taxol(TM)) and radiation therapy. Methods: Fourteen patients with a median age of 56 years (range 42-81) were treated. Paclitaxel was given every 3 weeks at a dose of 100 mg/m2 concurrently with external beam radiation. The patients treated included those who had failed to achieve a complete response (CR) to induction chemotherapy with cisplatin, 5- fluorouracil, and leucovorin (PFL), or who had locally advanced disease not previously treated. Results: Median follow-up from the initiation of treatment is 40 months (range 23-48). The majority of patients (13/14) achieved clinical CRs at the primary site. The development of responses was characterized by a long time course. Three patients who were nonresponders (NRs) to induction PFL chemotherapy were treated. One was a clinical CR at the primary site, one did not achieve a CR, and the other had residual disease in the neck. Four patients have failed, one with local-regional disease, one with a marginal failure, one with distant metastases, and one was not rendered disease-free by the treatment. As expected, significant local toxicity was observed. Most patients were managed with the aid of a percutaneous endoscopic gastrostomy (PEG). Two patients experienced significant moist desquamation and required treatment breaks of greater than 1 week. Conclusion: Paclitaxel can be given on a 3-week schedule at 100 mg/m2 concurrently with radiation. The preliminary results indicate good local responses and acceptable toxicity. This treatment approach merits further study in the treatment of head and neck malignancies, and should be considered as an option in other sites.",
keywords = "Combined modality therapy, Head and neck, Paclitaxel, Radiation",
author = "Tishler, {Roy B.} and Busse, {Paul M.} and Norris, {Charles M.} and Ren{\'e}́ Rossi and Mark Poulin and Lee Thornhill and Rosemary Costello and Peters, {Edward S.} and Colevas, {A. Dimitrios} and Posner, {Marshall R.}",
year = "1999",
month = "3",
day = "15",
doi = "10.1016/S0360-3016(98)00533-1",
language = "English (US)",
volume = "43",
pages = "1001--1008",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies

AU - Tishler, Roy B.

AU - Busse, Paul M.

AU - Norris, Charles M.

AU - Rossi, René́

AU - Poulin, Mark

AU - Thornhill, Lee

AU - Costello, Rosemary

AU - Peters, Edward S.

AU - Colevas, A. Dimitrios

AU - Posner, Marshall R.

PY - 1999/3/15

Y1 - 1999/3/15

N2 - Background: Combined modality therapy plays a central role in the management of head and neck malignancies. This study examined the feasibility and preliminary results of treating a group of patients using concurrent bolus paclitaxel (Taxol(TM)) and radiation therapy. Methods: Fourteen patients with a median age of 56 years (range 42-81) were treated. Paclitaxel was given every 3 weeks at a dose of 100 mg/m2 concurrently with external beam radiation. The patients treated included those who had failed to achieve a complete response (CR) to induction chemotherapy with cisplatin, 5- fluorouracil, and leucovorin (PFL), or who had locally advanced disease not previously treated. Results: Median follow-up from the initiation of treatment is 40 months (range 23-48). The majority of patients (13/14) achieved clinical CRs at the primary site. The development of responses was characterized by a long time course. Three patients who were nonresponders (NRs) to induction PFL chemotherapy were treated. One was a clinical CR at the primary site, one did not achieve a CR, and the other had residual disease in the neck. Four patients have failed, one with local-regional disease, one with a marginal failure, one with distant metastases, and one was not rendered disease-free by the treatment. As expected, significant local toxicity was observed. Most patients were managed with the aid of a percutaneous endoscopic gastrostomy (PEG). Two patients experienced significant moist desquamation and required treatment breaks of greater than 1 week. Conclusion: Paclitaxel can be given on a 3-week schedule at 100 mg/m2 concurrently with radiation. The preliminary results indicate good local responses and acceptable toxicity. This treatment approach merits further study in the treatment of head and neck malignancies, and should be considered as an option in other sites.

AB - Background: Combined modality therapy plays a central role in the management of head and neck malignancies. This study examined the feasibility and preliminary results of treating a group of patients using concurrent bolus paclitaxel (Taxol(TM)) and radiation therapy. Methods: Fourteen patients with a median age of 56 years (range 42-81) were treated. Paclitaxel was given every 3 weeks at a dose of 100 mg/m2 concurrently with external beam radiation. The patients treated included those who had failed to achieve a complete response (CR) to induction chemotherapy with cisplatin, 5- fluorouracil, and leucovorin (PFL), or who had locally advanced disease not previously treated. Results: Median follow-up from the initiation of treatment is 40 months (range 23-48). The majority of patients (13/14) achieved clinical CRs at the primary site. The development of responses was characterized by a long time course. Three patients who were nonresponders (NRs) to induction PFL chemotherapy were treated. One was a clinical CR at the primary site, one did not achieve a CR, and the other had residual disease in the neck. Four patients have failed, one with local-regional disease, one with a marginal failure, one with distant metastases, and one was not rendered disease-free by the treatment. As expected, significant local toxicity was observed. Most patients were managed with the aid of a percutaneous endoscopic gastrostomy (PEG). Two patients experienced significant moist desquamation and required treatment breaks of greater than 1 week. Conclusion: Paclitaxel can be given on a 3-week schedule at 100 mg/m2 concurrently with radiation. The preliminary results indicate good local responses and acceptable toxicity. This treatment approach merits further study in the treatment of head and neck malignancies, and should be considered as an option in other sites.

KW - Combined modality therapy

KW - Head and neck

KW - Paclitaxel

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0032943237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032943237&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00533-1

DO - 10.1016/S0360-3016(98)00533-1

M3 - Article

C2 - 10192347

AN - SCOPUS:0032943237

VL - 43

SP - 1001

EP - 1008

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -